rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

USANA Health Sciences, Inc.

USNA · NYSE

Health CarePharmaceuticalsNot moving yet

USNA stood above a rising 150-day average in 5 of the last 52 weekly readings, and has been out of that trend for the last 11 weeks. It is 15.7% below that average now. Pharmaceuticals: 32% of its 74 stocks in an uptrend (−7 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 11
Industry in uptrend
32% -7 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$1.8M
Officials’ trades on record
0
Institutions holding
129 (-2)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 5 of 52 weeks.

20 Apr – 19 Oct
26%34%43%Apr 26Jun 26Jul 26Sep 26Oct 26

Pharmaceuticals: A minority of its stocks are in an uptrend and the share has been slipping. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$626K$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months17
Buyers · sellers0 · 9
WhoDidSharesTraded
Brent NeidigCHIEF COMMERCIAL OFFICERsold5,002at $19.4516 Jun 2026filed 18 Jun 2026
Brent NeidigCHIEF COMMERCIAL OFFICERsold909at $20.0115 Jun 2026filed 16 Jun 2026
Brent NeidigCHIEF COMMERCIAL OFFICERsold1,602at $20.1512 Jun 2026filed 16 Jun 2026
Paul A. JonesCHIEF PEOPLE OFFICERsold5,561at $18.508 Jun 2026filed 8 Jun 2026
John Turman FlemingDirectorsold2,450at $17.931 Jun 2026filed 1 Jun 2026
Paul A. JonesCHIEF PEOPLE OFFICERsold6,813at $18.9528 May 2026filed 29 May 2026
G. Doug IiekkingCHIEF FINANCIAL OFFICERsold5,360at $18.7527 May 2026filed 28 May 2026
Gilbert A. FullerDirectorsold1,057at $18.6622 May 2026filed 26 May 2026
Joshua FoukasCHIEF LEGAL OFFICERsold3,791at $19.827 May 2026filed 8 May 2026
Gilbert A. FullerDirectorsold1,058at $17.0020 Mar 2026filed 20 Mar 2026
Peter BenedictCHIEF INFORMATION OFFICERsold4,553at $19.383 Mar 2026filed 3 Mar 2026
Joshua FoukasCHIEF LEGAL OFFICERsold4,461at $21.3520 Feb 2026filed 23 Feb 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders129-2 on the quarter
New · exited22 · 24
Reported value$245.1M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BlackRock, Inc.added · filed 7 Aug 20261,554,189$33.2M+363,773+30.6%
PZENA INVESTMENT MANAGEMENT LLCadded · filed 7 Aug 20261,205,587$25.7M+96,654+8.7%
RENAISSANCE TECHNOLOGIES LLCreduced · filed 13 Aug 2026958,520$20.5M-59,110−5.8%
DIMENSIONAL FUND ADVISORS LPadded · filed 11 Aug 2026837,426$17.9M+3,203+0.4%
Nantahala Capital Management, LLCunchanged · filed 14 Aug 2026810,074$17.3M00.0%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026487,370$10.4M+8,327+1.7%
Creative Planningadded · filed 13 Aug 2026417,971$8.9M+224,823+116.4%
AQR CAPITAL MANAGEMENT LLCadded · filed 14 Aug 2026408,086$8.7M+111,666+37.7%
VANGUARD PORTFOLIO MANAGEMENT LLCadded · filed 13 Aug 2026363,377$7.8M+25,103+7.4%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026283,165$6.0M+18,731+7.1%
31 Mar 2023 – 30 Jun 2026
113129145Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Kathryn Michelle Armstrong Company insiderCHIEF SCIENTIFIC OFFICER · last 25 Jul 20260 · 0
Peter Benedict Company insiderCHIEF INFORMATION OFFICER · last 25 Jul 20260 · 2
Frederic J. Winssinger Company insiderDirector · last 23 Jul 20260 · 8
Gilbert A. Fuller Company insiderDirector · last 23 Jul 20260 · 50
J. Scott Nixon Company insiderDirector · last 23 Jul 20260 · 1
John Turman Fleming Company insiderDirector · last 23 Jul 20260 · 9
Peggie Pelosi Company insiderDirector · last 23 Jul 20260 · 2
Timothy E. Wood Company insiderDirector · last 23 Jul 20260 · 8
Xia Ding Company insiderDirector · last 23 Jul 20260 · 1
Brent Neidig Company insiderCHIEF COMMERCIAL OFFICER · last 16 Jun 20260 · 15
Paul A. Jones Company insiderCHIEF PEOPLE OFFICER · last 8 Jun 20260 · 22
G. Doug Iiekking Company insiderCHIEF FINANCIAL OFFICER · last 27 May 20260 · 21

Same industry

ABBV AbbVieLeading+19%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 3 Jan 202678.3%
Operating profit marginFY 2025 · to 3 Jan 20264.0%
Free cash flow marginFY 2025 · to 3 Jan 20260.9%
Return on capital employedFY 2025 · to 3 Jan 20266.1%
Cash conversionFY 2025 · to 3 Jan 2026208%
Research spendFY 2025 · to 3 Jan 20261.2%
Share count trendFY 2025 · to 13 Mar 20261.0%
Cash and equivalentsFY 2025 · to 3 Jan 2026$158.4M
Free cash flowFY 2025 · to 3 Jan 2026$8.5M

Analyst forecasts

No analyst forecasts yet.